Loading
A phase 1/2 trial of RNK08954-01 in sarcomas, run by Ranok Therapeutics (Hangzhou) Co., Ltd., now recruiting.
A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation is a phase 1/2 interventional study registered as NCT06667544 by Ranok Therapeutics (Hangzhou) Co., Ltd., with 152 participants planned, started 2024-11-08 and due to reach its primary completion in 2026-12. Interventions recorded: RNK08954-01.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ranok Therapeutics (Hangzhou) and the tag pipeline.
Shares Ranok Therapeutics (Hangzhou) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares KRAS and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares KRAS and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/